Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W. Roloff, George Yaghmour, Jae H. Park et al.|Journal of Clinical Oncology|2024Cited by 36
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Rawan Faramand, Liora M. Schultz et al.|Blood Advances|2025Cited by 15
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Betsy Blunk, Gregory W. Roloff et al.|Blood Advances|2024Cited by 12
Development and validation of predictive models of early immune effector cell–associated hematotoxicityEmily C. Liang, Jordan Gauthier, Jennifer J. Huang et al.|Blood Advances|2024Cited by 11
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALLJordan Gauthier, Cameron J. Turtle, Emily C. Liang et al.|Blood Advances|2025Cited by 10